Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

Novartis Ireland were very proud that our Customer Engagement Platform team has won the Industry Pharma Award for Best Use of Technology. We were delighted that our team's innovation and commitment to ...

Novartis Ireland were delighted to recently mark its Collaboration Agreement with Deciphex, a Dublin-based digital pathology company, at a specially convened roundtable on Artificial Intelligence (AI) ...

Fabhalta is the only oral alternative complement pathway inhibitor to selectively target the underlying cause of C3G, an ultra-rare kidney disease with no approved treatments 2-5 Novartis continues to ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

When I first joined Novartis, I was nervous yet open to new experiences. I did not have experience in the pharmaceutical industry, and the dynamics and ways of working in marketing were completely ...

Job Title Sort ascending Business Location Site Date Posted Equipment Specialist (m/w/d), Kundl, Tirol, Österreich Regulär, Full time Innovative Medicines Austria Kundl Oct 18, 2024 Trainee Marketing ...

Explore opportunities with Novartis below.

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Job Title Sort ascending Business Location Site Date Posted Senior Scientist - in-vivo pharmacology/oncology (Radioligand Therapy) (80-100%*) Regular, Full time Pharma Research Switzerland Basel (City ...